Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/59104 |
Resumo: | Hepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5–15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important. |
id |
RCAP_92e890c5bc9025da37e22a2ad1870973 |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/59104 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in SpainHepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5–15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important.The authors thank patients and the Contributing members of the Spanish Group of Chronic Viral Hepatitis (SI1 Appendix) that have participated in this epidemiological survey and the Multidisciplinary Group of Viral Coinfection HIV/Hepatitis (COVIHEP). The Instituto de Salud Carlos III (ISCIII) provided financial support by the Grant (CP13/00098, PI15CIII/00031 and PI18CIII/00020 to VB). CP is financed by national funds via FCT through Norma Transitória—DL57/2016/CP1376/CT0004.Springer NatureRepositório da Universidade de LisboaPalladino, ClaudiaEzeonwumelu, Ifeanyi J.Maté, IreneBorrego, PedroMartínez-Román, PaulaArca-Lafuente, SoniaResino, SalvadorTaveira, NunoBriz, Verónica2023-08-31T13:35:52Z2020-122023-02-03T16:40:01Z2020-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/59104engPalladino C, Ezeonwumelu IJ, Mate-Cano I, Borrego P, Martínez-Román P, Arca-Lafuente S, et al. Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. Sci Rep [Internet]. 3 de agosto de 2020;10(1):13024. Disponível em: https://www.nature.com/articles/s41598-020-69692-7cv-prod-234458710.1038/s41598-020-69692-7info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:03:35Zoai:repositorio.ul.pt:10451/59104Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:06:42.932929Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
title |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
spellingShingle |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain Palladino, Claudia |
title_short |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
title_full |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
title_fullStr |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
title_full_unstemmed |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
title_sort |
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
author |
Palladino, Claudia |
author_facet |
Palladino, Claudia Ezeonwumelu, Ifeanyi J. Maté, Irene Borrego, Pedro Martínez-Román, Paula Arca-Lafuente, Sonia Resino, Salvador Taveira, Nuno Briz, Verónica |
author_role |
author |
author2 |
Ezeonwumelu, Ifeanyi J. Maté, Irene Borrego, Pedro Martínez-Román, Paula Arca-Lafuente, Sonia Resino, Salvador Taveira, Nuno Briz, Verónica |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Palladino, Claudia Ezeonwumelu, Ifeanyi J. Maté, Irene Borrego, Pedro Martínez-Román, Paula Arca-Lafuente, Sonia Resino, Salvador Taveira, Nuno Briz, Verónica |
description |
Hepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5–15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12 2020-12-01T00:00:00Z 2023-08-31T13:35:52Z 2023-02-03T16:40:01Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/59104 |
url |
http://hdl.handle.net/10451/59104 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Palladino C, Ezeonwumelu IJ, Mate-Cano I, Borrego P, Martínez-Román P, Arca-Lafuente S, et al. Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. Sci Rep [Internet]. 3 de agosto de 2020;10(1):13024. Disponível em: https://www.nature.com/articles/s41598-020-69692-7 cv-prod-2344587 10.1038/s41598-020-69692-7 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Springer Nature |
publisher.none.fl_str_mv |
Springer Nature |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134620062580736 |